ENERGI-F703 for Diabetic Foot Ulcers Phase II Study
A Randomized, Double-Blind, Vehicle-controlled, Parallel, Phase II Study to Evaluate Efficacy and Safety of ENERGI-F703 in Subjects With Diabetic Foot Ulcers
Sponsor: A2 Healthcare Taiwan Corporation
This PHASE2 trial investigates Diabetes Mellitus and Diabetic Foot and is currently completed. A2 Healthcare Taiwan Corporation leads this study, which shows 10 recorded versions since 2017 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
10 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE2
-
Dec 2020 — Jan 2021 [monthly]
Completed PHASE2
Status: Recruiting → Completed
-
Oct 2019 — Dec 2020 [monthly]
Recruiting PHASE2
▶ Show 5 earlier versions
-
Jul 2018 — Oct 2019 [monthly]
Recruiting PHASE2
-
Jun 2018 — Jul 2018 [monthly]
Recruiting PHASE2
-
Aug 2017 — Jun 2018 [monthly]
Recruiting PHASE2
Status: Not Yet Recruiting → Recruiting
-
Feb 2017 — Aug 2017 [monthly]
Not Yet Recruiting PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Not Yet Recruiting PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- A2 Healthcare Taiwan Corporation
- Energenesis Biomedical Co., Ltd.
For direct contact, visit the study record on ClinicalTrials.gov .